These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 28979172)

  • 1. Reversing factor Xa inhibitors - clinical utility of andexanet alfa.
    Kaatz S; Bhansali H; Gibbs J; Lavender R; Mahan CE; Paje DG
    J Blood Med; 2017; 8():141-149. PubMed ID: 28979172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies.
    Escolar G; Diaz-Ricart M; Arellano-Rodrigo E
    Drugs Today (Barc); 2017 May; 53(5):271-282. PubMed ID: 28650000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values.
    Siddiqui F; Tafur A; Ramacciotti LS; Jeske W; Hoppensteadt D; Ramacciotti E; Iqbal O; Fareed J
    Clin Appl Thromb Hemost; 2019; 25():1076029619863493. PubMed ID: 31298056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists.
    Desai NR; Cornutt D
    Hosp Pract (1995); 2019 Aug; 47(3):113-122. PubMed ID: 31317796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
    Tummala R; Kavtaradze A; Gupta A; Ghosh RK
    Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
    Milling TJ; Middeldorp S; Xu L; Koch B; Demchuk A; Eikelboom JW; Verhamme P; Cohen AT; Beyer-Westendorf J; Gibson CM; Lopez-Sendon J; Crowther M; Shoamanesh A; Coppens M; Schmidt J; Albaladejo P; Connolly SJ;
    Circulation; 2023 Mar; 147(13):1026-1038. PubMed ID: 36802876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy.
    Sartori M; Cosmi B
    J Thromb Thrombolysis; 2018 Apr; 45(3):345-352. PubMed ID: 29372400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Strategies for the Management of Bleeding Associated with Direct Oral Anticoagulants and a Review of Investigational Reversal Agents.
    Kaide CG; Gulseth MP
    J Emerg Med; 2020 Feb; 58(2):217-233. PubMed ID: 31831187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Andexanet alfa (ONDEXXYA
    Yajima T; Higashimori M; Takata C; Sasabe T
    Nihon Yakurigaku Zasshi; 2023; 158(1):89-100. PubMed ID: 36596498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers.
    Lu G; Conley PB; Leeds JM; Karbarz MJ; Levy GG; Mathur VS; Castillo J; Crowther M; Curnutte JT
    Blood Adv; 2020 Feb; 4(4):728-739. PubMed ID: 32092140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA).
    Rogers KC; Finks SW
    Am J Med; 2019 Jan; 132(1):38-41. PubMed ID: 30053385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures.
    Levy JH
    Am J Med; 2016 Nov; 129(11S):S47-S53. PubMed ID: 27569675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of an andexanet alfa administration protocol guided by drug-specific quantitative anti-Xa assays.
    Lanham HT; Viriyakitja W; Vestal M; Welsby I; Kram B
    J Thromb Thrombolysis; 2024 Feb; 57(2):285-292. PubMed ID: 37932587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct-Acting Oral Anticoagulants and Their Reversal Agents-An Update.
    Kustos SA; Fasinu PS
    Medicines (Basel); 2019 Oct; 6(4):. PubMed ID: 31618893
    [No Abstract]   [Full Text] [Related]  

  • 15. Apixaban and rivaroxaban anti-Xa level utilization for guidance of administration of andexanet alfa: a case series.
    Morton C; Lista A; Jakowenko N; Salazar E; Donahue KR
    J Thromb Thrombolysis; 2022 Jan; 53(1):235-239. PubMed ID: 34236614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How can we reverse bleeding in patients on direct oral anticoagulants?
    Crowther M; Cuker A
    Kardiol Pol; 2019; 77(1):3-11. PubMed ID: 30338501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Andexanet Alfa (Andexxa) Formulary Review.
    Beik N; Reddy P; Sylvester KW; Connell NT; Giugliano RP; Piazza G; Connors JM
    Crit Pathw Cardiol; 2019 Jun; 18(2):66-71. PubMed ID: 31094731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Idarucizumab and Andexanet Alfa on DOAC Plasma Concentration and ClotPro
    Oberladstätter D; Schlimp CJ; Zipperle J; Osuchowski MF; Voelckel W; Grottke O; Schöchl H
    J Clin Med; 2021 Aug; 10(16):. PubMed ID: 34441771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal agents for use with direct and indirect anticoagulants.
    Smythe MA; Trujillo T; Fanikos J
    Am J Health Syst Pharm; 2016 May; 73(10 Suppl 2):S27-48. PubMed ID: 27147456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Andexanet Alfa for Reversing Factor Xa Inhibition.
    Sible AM; Nawarskas JJ
    Cardiol Rev; 2019; 27(2):108-111. PubMed ID: 30362966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.